Alzheimer's Disease –
Novel Combination Therapy
A De-Risked, Dual-Mechanism Approach to Alzheimer's Disease
The Problem: Therapy for Alzheimer's remains inadequate
The two current approved drugs lack effectiveness, do not target the root cause and have safety concerns.
The Solution: A De-Risked, Dual-Mechanism Approach to Alzheimer's Disease
Nabri targets neuroinflammation at its root cause with two synergistic compounds in a first-in-class combination.
The Approach: Why Nabri Wins
← Scroll to see full comparison →
| Dimension | Amyloid Antibodies (Lecanemab/Donanemab) | Novel Small Molecules (Typical Pipeline) | Nabri: Dual Synergistic Therapy |
|---|---|---|---|
| Safety Profile | ARIA Risk (Brain Bleeds) in 30%+ Patients | Unknown – Full Safety Trials Required | ✓ Preclinical Safety Established |
| Patient Pop. | Early-Stage Only (~15M US) | Varies – Mainly Early-Stage | ✓ Early + Moderate AD |
| Mechanism | Amyloid Clearance (Downstream Symptom) | Single Target (High Failure Risk) | ✓ Dual-Target – Prevents Neuro Inflammation & Degeneration |
| IP Position | Established – Widely Licensed | Varies | ✓ Provisional Filed |
| Competitive Landscape | Crowded – Major Pharma Dominates | Moderate | ✓ Zero Direct Competitors |
Digital Twin Trial Innovation: Redefining Trial Economics
Nabri's Phase 1 trial deploys AI-generated digital twins — computational replicas of each enrolled patient built from biological, clinical, and genomic profiles. Rather than randomizing patients to a placebo arm (which delays enrollment, inflates cost, and raises ethical concerns in a disease with no effective treatment alternatives), each patient is compared to their own virtual counterpart.
This adaptive design strategy has regulatory precedent and is increasingly recognized by FDA as acceptable for proof-of-concept studies in conditions with high unmet need. The model can extend into Phase 2, compressing the path to licensable efficacy data.
Strategic Trial Advantages
- Placebo Arm — save patients by using digital twins and significantly reduce cost and time
- 2× faster enrollment — all screened patients can participate; no 50/50 randomization loss
- AI-powered biomarker response — plasma markers + imaging generate real-time efficacy signals
- Cost efficient structure vs. traditional RCT for equivalent statistical power